A perspective on more effective GPCR-targeted drug discovery efforts

Expert Opinion on Drug Discovery

Volumn 3, Issue 4, 2008, Pages 375-389

  Gilchrist, Annette ^a  

^a Caden Biosciences   (United States)

Author keywords

Agonist directed trafficking; Allosteric; Allosterism; Biased agonism; Densensitization; Drug discovery; Functional seleaivity; G protein; G ; G ; G ; G protein coupled receptor; Heterotrimer; High throughput screening; Internalization; Screening; Signal transduction

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ADRENERGIC RECEPTOR AFFECTING AGENT; ALPHA 2A ADRENERGIC RECEPTOR; ATOSIBAN; BETA 2 ADRENERGIC RECEPTOR; BOMBESIN; CCG 4986; DEACETYLLEVONANTRADOL; DICHLORISOPRENALINE; DOPAMINE 2 RECEPTOR; G PROTEIN COUPLED RECEPTOR; GLUCAGON; GUANINE NUCLEOTIDE BINDING PROTEIN; HISTAMINE H3 RECEPTOR AGONIST; KAPPA OPIATE RECEPTOR; LEVOMEDETOMIDINE; MEDETOMIDINE; METHANANDAMIDE; N,N DIALLYLTYROSYL 2 METHYLALANYL 2 METHYLALANYLPHENYLALANYLLEUCINE; OXYNTOMODULIN; PARATHYROID HORMONE RECEPTOR; PARATHYROID HORMONE[1-34]; PRECLAMOL; PROPRANOLOL; PROTEIN INHIBITOR; PROXYFAN; QUINPIROLE; SALVINORIN A; UNINDEXED DRUG; UROCORTIN;

CANCER INVASION; CARCINOGENESIS; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SCREENING; DRUG SELECTIVITY; DRUG TARGETING; GENE IDENTIFICATION; HEART FAILURE; HIGH THROUGHPUT SCREENING; HUMAN; INTERNALIZATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 42949163503     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.3.4.375     Document Type: Review

References (182)

1. Bockaert J, Dumuis A, Fagni L, et al. GPCR-GIP networks: a first step in the discovery of new therapeutic drugs? Curr Opin Drug Discov Dev 2004;7:649-57
2. Eglen R, Bosse R, Reisine T. Emerging concepts of guanine nucleotide-binding protein-coupled receptor (GPCR) function and implications for high-throughput screening. Assay Drug Dev Technol 2007;5:425-51
3. Palczewski K, Kumasaka T, Hori T, et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 2000;289:739-45
4. Rosenbaum D, Cherezov V, Hanson M, et al. GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science 2007;318:1266-73
5. Cherezov V, Rosenbaum D, Hanson M, et al. High-resolution crystal structure of all engineered human beta2-adrenergic G protein-coupled receptor. Science 2007;318:1258-65
6. Rasmussen S, Choi H, Rosenbaum D, et al. Crystal structure of the human beta2 adrenergic G protein-coupled receptor. Nature 2007;450:383-7
7. Yeagle P, Albert A. G protein coupled receptor structure. Biochim Biophys Acta 2007;1768:808-24
8. Werner K, Richter C, Klein-Seetharaman J, et al. Isotope labeling of mammalian GPCRs in HEK293 cells and characterization of the C-terminus of bovine rhodopsin by high resolution liquid NMR spectroscopy. J Biomol NMR 2008;40:49-53
9. Martinelli A, Tuccinardi T. Molecular modeling of adenosine receptors: new results and trends. Med Res Rev 2008;28:247-77
10. Heo J, Han S, Vaidehi N, et al. Prediction of the 3D structure of FMRF-amide neuropeptides bound to the mouse MrgC11 GPCR and experimental validation. Chembiochem 2007;8:1527-39
11. Cavasotto C, Orry A, Murgolo N, et al. Discovery of novel chemotypes to a G protein-coupled receptor through ligand-steered homology modeling and structure-based virtual screening. J Med Chem 2008;51:581-8
12. Sun Y, Huang J, Xiang Y, et al. Dosage-dependent switch from G protein-coupled to G protein-independent signaling by a GPCR. EMBO J 2007;26:53-64
13. Charest P, Oligny-Longpre G, Bonin H, et al. The V2 vasopressin receptor stimulates ERK1/2 activity independently of heterotrimeric G protein signaling. Cell Signal 2007;19:32-41
14. Blumer J, Smrcka A, Lanier S. Mechanistic pathways and biological roles for receptor-independent activators of G protein signaling. Pharmacol Ther 2007;113:488-506
15. Pyne N, Waters C, Moughal N, et al. Experimental systems for studying the role of G protein-coupled receptors in receptor tyrosine kinase signal transduction. Methods Enzymol 2004;390:451-75
16. Delcourt N, Bockaert J, Marin P. GPCR-jacking: from a new route in RTK signaling to a new concept in GPCR activation. Trends Pharmacol Sci 2007;28:602-7
17. Thomas S, Bhola N, Zhang Q, et al. Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma. Cancer Res 2006;66:11831-9
18. Bhola N, Grandis J. Crosstalk between G protein-coupled receptors and epidermal growth factor receptor in cancer. Front Biosci 2008;13:1857-65
19. Thomsen W, Frazer J, Unett D. Functional assays for screening GPCR targets. Curr Opin Biotechnol 2005;16;655-65
20. Kostenis E. G proteins in drug screening: from analysis of receptor-G protein specificity to manipulation of GPCR-mediated signaling pathways. Curr Pharm Des 2006;12:1703-15
21. Kisselev O, Gautam N. Specific interaction with rhodopsin is dependent on the gamma subunit type in a G protein. J Biol Chem 1993;268:24519-22
22. Kisselev O, Pronin A, Ermolaeva M, et al. Receptor-G protein coupling is established by a potential conformational switch in the beta gamma complex. Proc Natl Acad Sci USA 1995;92:9102-6
23. Kleuss C, Scherubl H, Hescheler J, et al. Selectivity in signal transduction determined by gamma subunits of heterotrimeric G proteins. Science 1993;259:832-4
24. Andreopoulos S, Li P, Warsh J. Developmental expression of G alpha o and G alpha s isoforms in PC12 cells: relationship to neurite outgrowth. Brain Res Dev Brain Res 1995;88:30-6
25. Wilson B, Komuro M, Farquhar M. Cellular variations in heterotrimeric G protein localization and expression in rat pituitary. Endocrinology 1994;134:233-44
26. Hynes T, Hughes T, Berlot C. Cellular localization of GFP-tagged alpha subunits. Methods Mol Biol 2004;237:233-46
27. Hubbard K, Hepler J. Cell signaling diversity of the Gqalpha family of heterotrimeric G proteins. Cell Signal 2006;18:135-50
28. Downes G, Gautam N. The G protein subunit gene families. Genomics 1999;62:544-52
29. Wedegaertner P, Wilson P, Bourne H. Lipid modifications of trimeric G proteins. J Biol Chem 1995;270:503-6
30. Escriba P, Wedegaertner P, Goni F, et al. Lipid-protein interactions in GPCR-associated signaling. Biochim Biophys Acta 2007;1768:836-52
31. Milligan G, Parenti M, Magee A. The dynamic role of palmitoylation in signal transduction. Trends Biochem Sci 1995;20:181-7
32. Barclay E, O'Reilly M, Milligan G. Activation of an alpha2A-adrenoceptor-Galphao1 fusion protein dynamically regulates the palmitoylation status of the G protein but not of the receptor. Biochem J 2005;385:197-206
33. Wells C, Dingus J, Hildebrandt J. Role of the chaperonin CCT/TRiC complex in G protein betagamma-dimer assembly. J Biol Chem 2006;281:20221-32
34. Clapham D, Neer E. G protein beta gamma subunits. Ann Rev Pharmacol Toxicol 1997;37:167-203
35. Tang W, Tu Y, Nayak S, et al. Gbetagamma inhibits Galpha GTPase-activating proteins by inhibition of Galpha-GTP binding during stimulation by receptor. J Biol Chem 2006;281:4746-53
36. Kisselev O, Ermolaeva M, Gautam N. A farnesilated domain in the G protein gamma subunit is a specific determinant of receptor coupling. J Biol Chem 1994;269:21399-402
37. Sprang S. G protein mechanisms: insights from structural analysis. Ann Rev Biochem 1997;66:639-78
38. Bunemann M, Frank M, Lohse M. Gi protein activation in intact cells involves subunit rearrangement rather than dissociation. Proc Natl Acad Sci USA 2003;100:16077-82
39. Frank M, Thumer L, Lohse M, et al. G Protein activation without subunit dissociation depends on a G{alpha} (i)-specific region. J Biol Chem 2005;280:24584-90
40. Birnbaumer L. Expansion of signal transduction by G proteins. The second 15 years or so: from 3 to 16 alpha subunits plus betagamma dimers. Biochim Biophys Acta 2007;1768:772-93
41. Cabrera-Vera T, Vanhauwe J, Thomas T, et al. Insights into G protein structure, function, and regulation. Endocr Rev 2003;24:765-81
42. Neubig R, Connolly M, Remmers A. Rapid kinetics of G protein subunit association: a rate-limiting conformational change? FEBS Lett 1994;355:251-3
43. Muradov K, Artemyev N. Coupling between the N- and C-terminal domains influences transducin-alpha intrinsic GDP/GTP exchange. Biochemistry 2000;39:3937-42
44. Thomas T, Bae H, Medkova M, et al. An intramolecular contact in Galpha transducin that participates in maintaining its intrinsic GDP release rate. Mol Cell Biol Res Commun 2001;4:282-91
45. Arshavsky V, Dumke C, Zhu Y, et al. Regulation of transducin GTPase activity in bovine rod outer segments. J Biol Chem 1994;269:19882-7
46. Tesmer J, Berman D, Gilman A, et al. Structure of RGS4 bound to AlF4-activated G(i alpha1): stabilization of the transition state for GTP hydrolysis. Cell Signal 1997;89:251-61
47. Willars G. Mammalian RGS proteins: multifunctional regulators of cellular signaling. Semin Cell Dev Biol 2006;17:363-76
48. Tinker A. The selective interactions and functions of regulators of G protein signaling. Semin Cell Dev Biol 2006;17:377-82
49. Jean-Baptiste G, Yang Z, Greenwood M. Regulatory mechanisms involved in modulating RGS function. Cell Mol Life Sci 2006;63:1969-85
50. Tobin A. G protein-coupled receptor phosphorylation: where, when and by whom. Br J Pharmacol 2008 [Epub ahead of date]
51. Lefkowitz R, Rajagopal K, Whalen E. New roles for beta-arrestins in cell signaling: not just for seven-transmembrane receptors. Mol Cell 2006;24:643-52
52. Engstrom M, Savola J, Wurster S. Differential efficacies of somatostatin receptor agonists for G protein activation and desensitization of somatostatin receptor subtype 4-mediated responses. J Pharmacol Exp Ther 2006;316:1262-8
53. Keith D, Murray S, Zaki P, et al. Morphine activates opioid receptors without causing their rapid internalization. J Biol Chem 1996;271:19021-4
54. Blake A, Bot G, Freeman J, et al. Differential opioid agonist regulation of the mouse mu opioid receptor. J Biol Chem 1997;272:782-90
55. Roettger B, Ghanekar D, Rao R, et al. Antagonist-stimulated internalization of the G protein-coupled cholecystokinin receptor. Mol Pharmacol 1997;51:357-62
56. Yu Y, Zhang L, Yin X, et al. Mu opioid receptor phosphorylation, desensitization, and ligand efficacy. J Biol Chem 1997;272:28869-74
57. Mhaouty-Kodja S, Barak L, Scheer A, et al. Constitutively active alpha-1b adrenergic receptor mutants display different phosphorylation and internalization features. Mol Pharmacol 1999;55:339-47
58. Lembo P, Ghahremani M, Albert P. Receptor selectivity of the cloned opossum G protein-coupled receptor kinase 2 (GRK2) in intact opossum kidney cells: role in desensitization of endogenous alpha2C-adrenergic but not serotonin 1B receptors. Mol Endocrinol 1999;13:138-47
59. Reiter E, Marion S, Robert F, et al. Kinase-inactive G protein-coupled receptor kinases are able to attenuate follicle-stimulating hormone-induced signaling. Biochem Biophys Res Commun 2001;282:71-8
60. Dhami G, Anborgh P, Dale L, et al. Phosphorylation-independent regulation of metabotropic glutamate receptor signaling by G protein-coupled receptor kinase 2. J Biol Chem 2002;277:25266-72
61. Perroy J, Adam L, Qanbar R, et al. Phosphorylation-independent desensitization of GABA(B) receptor by GRK4. EMBO J 2003;22:3816-24
62. Moore C, Milano S, Benovic J. Regulation of receptor trafficking by GRKs and arrestins. Ann Rev Physiol 2007;69:451-82
63. Binda A, Kabbani N, Lin R, et al. D2 and D3 dopamine receptor cell surface localization mediated by interaction with protein 4.1N. Mol Pharmacol 2002;62:507-13
64. Weber B, Schaper C, Scholz J, et al. Interaction of the amyloid precursor like protein 1 with the alpha2A-adrenergic receptor increases agonist-mediated inhibition of adenylyl cyclase. Cell Signal 2006;18:1748-57
65. Cui T, Nakagami H, Iwai M, et al. ATRAP, novel AT1 receptor associated protein, enhances internalization of AT1 receptor and inhibits vascular smooth muscle cell growth. Biochem Biophys Res Commun 2000;279:938-41
66. Lezcano N, Mrzljak L, Eubanks S, et al. Dual signaling regulated by calcyon, a D1 dopamine receptor interacting protein. Science 2000;287:1660-4
67. Binda A, Kabbani N, Levenson R. Regulation of dense core vesicle release from PC12 cells by interaction between the D2 dopamine receptor and calcium-dependent activator protein for secretion (CAPS). Biochem Pharmacol 2005;69:1451-61
68. Rochdi M, Laroche G, Dupre E, et al. Nm23-H2 interacts with a G protein-coupled receptor to regulate its endocytosis through an Rac1-dependent mechanism. J Biol Chem 2004;279:18981-9
69. Hu L, Chen W, Martin N, et al. GIPC interacts with the beta1-adrenergic receptor and regulates beta1-adrenergic receptor-mediated ERK activation. J Biol Chem 2003;278:26295-301
70. Lin S, Arai A, Wang Z, et al. The carboxyl terminus of the prolactin-releasing peptide receptor interacts with PDZ domain proteins involved in alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor clustering. Mol Pharmacol 2001;60:916-23
71. Whistler J, Enquist J, Marley A, et al. Modulation of postendocytic sorting of G protein-coupled receptors. Science 2002;297:615-20
72. Jeanneteau F, Diaz J, Sokoloff P, et al. Interactions of GIPC with dopamine D2, D3 but not D4 receptors define a novel mode of regulation of G protein-coupled receptors. Mol Biol Cell 2004;15:696-705
73. Griffon N, Jeanneteau F, Prieur F, et al. CLIC6, a member of the intracellular chloride channel family, interacts with dopamine D(2)-like receptors. Brain Res Mol Brain Res 2003;117:47-57
74. Kabbani N, Negyessy L, Lin R, et al. Interaction with neuronal calcium sensor NCS-1 mediates desensitization of the D2 dopamine receptor. J Neurosci 2002;22:8476-86
75. Sneddon W, Syme C, Bisello A, et al. Activation-independent parathyroid hormone receptor internalization is regulated by NHERF1 (EBP50). J Biol Chem 2003;278:43787-96
76. Anborgh P, Godin C, Pampillo M, et al. Inhibition of metabotropic glutamate receptor signaling by the huntingtin-binding protein optineurin. J Biol Chem 2005;280:34840-8
77. Seachrist J, Laporte S, Dale L, et al. Rab5 association with the angiotensin II type 1A receptor promotes Rab5 GTP binding and vesicular fusion. J Biol Chem 2002;277:679-85
78. Abramow-Newerly M, Roy A, Nunn C, et al. RGS proteins have a signaling complex: interactions between RGS proteins and GPCRs, effectors, and auxiliary proteins. Cell Signal 2006;18:579-91
79. Bhattacharya M, Babwah A, Godin C, et al. Ral and phospholipase D2-dependent pathway for constitutive metabotropic glutamate receptor endocytosis. J Neurosci 2004;24:8752-61
80. Canela L, Lujan R, Lluis C, et al. The neuronal Ca(2+)-binding protein 2 (NECAB2) interacts with the adenosine A(2A) receptor and modulates the cell surface expression and function of the receptor. Mol Cell Neurosci 2007;36:1-12
81. He F, Qiao Z, Cai J, et al. Involvement of HSP-90 in CB2 cannabinoid receptor-mediated cell migration - a new role of HSP-90 in migration signaling of a G protein-coupled receptor. Mol Pharmacol 2007 [Epub ahead of print]
82. Kabbani N, Levenson R. A proteomic approach to receptor signaling: molecular mechanisms and therapeutic implications derived from discovery of the dopamine D(2) receptor signalplex. Eur J Pharmacol 2007 [Epub ahead of print]
83. Langmead C, Christopoulos A. Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox. Trends Pharmacol Sci 2006;27:475-81
84. Christopoulos A, Kenakin T. G protein-coupled receptor allosterism and complexing. Pharmacol Rev 2002;54:323-74
85. Christopoulos A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat Rev Drug Discov 2002;1:198-210
86. Raddatz R, Schaffhauser H, Marino M. Allosteric approaches to the targeting of G protein-coupled receptors for novel drug discovery: a critical assessment. Biochem Pharmacol 2007;74:383-91
87. May L, Christopoulos A. Allosteric modulators of G protein-coupled receptors. Curr Opin Pharmacol 2003;3:551-6
88. Lewandowicz A, Vepsalainen J, Laitinen J. The 'allosteric modulator' SCH-202676 disrupts G protein-coupled receptor function via sulfhydryl-sensitive mechanisms. Br J Pharmacol 2006;147:422-9
89. Jakubik J, Bacakova L, Lisa V, et al. Activation of muscarinic acetylcholine receptors via their allosteric binding sites. Proc Natl Acad Sci USA 1996;93:8705-9
90. Thomas E, Carson M, Neal M, et al. Unique allosteric regulation of 5-hydroxytryptamine receptor-mediated signal transduction by oleamide. Proc Natl Acad Sci USA 1997;94:14115-9
91. Kinney G, O'Brien J, Lemaire W, et al. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J Pharmacol Exp Ther 2005;313:199-206
92. Holst B, Elling C, Schwartz T. Metal ion-mediated agonism and agonist enhancement in melanocortin MC1 and MC4 receptors. J Biol Chem 2002;277:47662-70
93. Holst B, Brandt E, Bach A, et al. Nonpeptide and peptide growth hormone secretagogues act both as ghrelin receptor agonist and as positive or negative allosteric modulators of ghrelin signaling. Mol Endocrinol 2005;19:2400-11
94. Binet V, Brajon C, Le Corre L, et al. The heptahelical domain of GABA(B2) is activated directly by CGP7930, a positive allosteric modulator of the GABA(B) receptor. J Biol Chem 2004;279:29085-91
95. Knudsen L, Kiel D, Teng M, et al. Small-molecule agonists for the glucagon-like peptide 1 receptor. Proc Natl Acad Sci USA 2007;104:937-42
96. Schwartz T, Holst B. Ago-allosteric modulation and other types of allostery in dimeric 7TM receptors. J Recept Signal Transduct Res 2006;26:107-28
97. Gbahou F, Rouleau A, Morisset S, et al. Protean agonism at histamine H3 receptors in vitro and in vivo. Proc Natl Acad Sci USA 2003;100:11086-91
98. Milligan G. Principles: extending the utility of [35S]GTP gamma S binding assays. Trends Pharmacol Sci 2003;24:87-90
99. Alberts G, Pregenzer J, Im W. Advantages of heterologous expression of human D2long dopamine receptors in human neuroblastoma SH-SY5Y over human embryonic kidney 293 cells. Br J Pharmacol 2000;131:514-20
100. Molinari P, Casella I, Costa T. Functional complementation of high-efficiency resonance energy transfer: a new tool for the study of protein binding interactions in living cells. Biochem J 2008;409:251-61
101. Galés C, Rebois R, Hogue M, et al. Real-time monitoring of receptor and G protein interactions in living cells. Nat Methods 2005; 2:177-84
102. Nobles M, Benians A, Tinker A. Heterotrimeric G proteins precouple with G protein-coupled receptors in living cells. Proc Natl Acad Sci USA 2005;102:18706-11
103. Lohse M, Hoffmann C, Nikolaev V, et al. Kinetic analysis of G protein-coupled receptor signaling using fluorescence resonance energy transfer in living cells. Adv Protein Chem 2007;74:167-88
104. Briddon S, Hill S. Pharmacology under the microscope: the use of fluorescence correlation spectroscopy to determine the properties of ligand-receptor complexes. Trends Pharmacol Sci 2007;28:637-45
105. De Lean A, Stadel J, Lefkowitz R. A ternary complex model explains the agonist-specific binding properties of the adenylyl cyclase-coupled beta-adrenergic receptor. J Biol Chem 1980;255:7108-17
106. Harrison C, Traynor J. The [35S] GTPgammaS binding assay: approaches and applications in pharmacology. Life Sci 2003;74:489-508
107. DeLapp N. The antibody-capture [(35)S] GTPgammaS scintillation proximity assay: a powerful emerging technique for analysis of GPCR pharmacology. Trends Pharmacol Sci 2004;25:400-1
108. Bertin B, Freissmuth M, Jockers R, et al. Cellular signaling by an agonist-activated receptor/Gs alpha fusion protein. Proc Natl Acad Sci USA 1994;91:8827-31
109. Milligan G, Parenty G, Stoddart L, et al. Novel pharmacological applications of G protein-coupled receptor-G protein fusions. Curr Opin Pharmacol 2007 [Epub ahead of print]
110. Molinari P, Ambrosio C, Riitano D, et al. Promiscuous coupling at receptor-Galpha fusion proteins. The receptor of one covalent complex interacts with the alpha-subunit of another. J Biol Chem 2003;278:15778-88
111. Suga H, Haga T. Ligand screening system using fusion proteins of G protein-coupled receptors with G protein alpha subunits. Neurochem Int 2007;51:140-64
112. Van Dop C, Yamanaka G, Steinberg F, et al. ADP-ribosylation of transducin by pertussis toxin blocks the light-stimulated hydrolysis of GTP and cGMP in retinal photoreceptors. J Biol Chem 1984;259:23-6
113. Umemori H, Inoue T, Kume S, et al. Activation of the G protein Gq/11 through tyrosine phosphorylation of the alpha subunit. Science 1997;276:1878-81
114. McFadzean I, Caulfield M, Vallis Y, et al. Injection of antisera into cells to study G protein regulation of channel function. Methods Enzymol 1994;238:357-64
115. Hamm HE, Deretic D, Arendt A, et al. Site of G protein binding to rhodopson mapped with synthetic peptides from the α subunit. Science 1988;241:832-5
116. Rasenick M, Watanabe M, Lazarevic M, et al. Synthetic peptides as probes for G protein function. Carboxyl-terminal G alpha s peptides mimic Gs and evoke high affinity agonist binding to beta-adrenergic receptors. J Biol Chem 1994;269:21519-25
117. Gilchrist A, Mazzoni M, Dineen B, et al. Antagonists of the receptor-G protein interface block Gi-coupled signal transduction. J Biol Chem 1998;273:14912-9
118. D'Ursi A, Giusti L, Albrizio S, et al. A membrane-permeable peptide containing the last 21 residues of the G alpha(s) carboxyl terminus inhibits G(s)-coupled receptor signaling in intact cells: correlations between peptide structure and biological activity. Mol Pharmacol 2006;69:727-36
119. Conklin B, Farfel Z, Lustig K, et al. Substitution of three amino acids switches receptor specificity of Gq alpha to that of Gi alpha. Nature 1993;363:274-6
120. Kostenis E, Conklin B, Wess J. Molecular basis of receptor/G protein coupling selectivity studied by coexpression of wild type and mutant m2 muscarinic receptors with mutant G alpha(q) subunits. Biochemistry 1997;36:1487-95
121. Blahos Jn, Mary S, Perroy J, et al. Extreme C terminus of G protein α-subunits contains a site that discriminates between Gi-coupled metabotropic glutamate receptors. J Biol Chem 1998;273:25765-9
122. Conklin B, Herzmark P, Ishida S, et al. Carboxyl-terminal mutations of Gq alpha and Gs alpha that alter the fidelity of receptor activation. Mol Pharmacol 1996;50:885-90
123. Gilchrist A, Bunemann M, Li A, et al. A dominant-negative strategy for studying roles of G proteins in vivo. J Biol Chem 1999;274:6610-6
124. Gilchrist A, Vanhauwe J, Li A, et al. G alpha minigenes expressing C-terminal peptides serve as specific inhibitors of thrombin-mediated endothelial activation. J Biol Chem 2001;276:25672-9
125. Gilchrist A, Li A, Hamm H. G alpha COOH-terminal minigene vectors dissect heterotrimeric G protein signaling. Sci STKE 2002;5:PL1
126. Lin F, Sepich D, Chen S, et al. Essential roles of G{alpha} 12/13 signaling in distinct cell behaviors driving zebrafish convergence and extension gastrulation movements. J Cell Biol 2005;169:777-87
127. Singh A, Gilchrist A, Voyno-Yasenetskaya T, et al. G alpha 12/G alpha13 subunits of heterotrimeric G proteins mediate parathyroid hormone activation of phospholipase D in UMR-106 osteoblastic cells. Endocrinology 2005;146:2171-5
128. Lee C, Rivera R, Dubin A, et al. LPA(4)/GPR23 is a lysophosphatidic acid (LPA) receptor utilizing G(s)-, G(q)/G(i)-mediated calcium signaling and G(12/13)-mediated Rho activation. J Biol Chem 2007;282:4310-7
129. Coffield V, Helms W, Jiang Q, et al. Galpha13 mediates a signal that is essential for proliferation and survival of thymocyte progenitors. J Exp Med 2004;200:1315-24
130. Coward P, Chan S, Wada H, et al. Chimeric G proteins allow a high-throughput signaling assay of Gi-coupled receptors. Anal Biochem 1999;270:242-8
131. Xing H, Tran H, Knapp T, et al. A fluorescent reporter assay for the detection of ligands acting through Gi protein-coupled receptors. J Recept Signal Transduct Res 2000;20:189-210
132. Kowal D, Nawoschik S, Ochalski R, et al. Functional calcium coupling with the human metabotropic glutamate receptor subtypes 2 and 4 by stable co-expression with a calcium pathway facilitating G protein chimera in Chinese hamster ovary cells. Biochem Pharmacol 2003;66:785-90
133. Gopalakrishnan S, Moreland R, Kofron J, et al. A cell-based microarrayed compound screening format for identifying agonists of G protein-coupled receptors. Anal Biochem 2003;321:192-201
134. New D, Wong Y. Characterization of CHO cells stably expressing a G alpha 16/z chimera for high-throughput screening of GPCRs. Assay Drug Dev Technol 2004;2:269-80
135. Hazari A, Lowes V, Chan J, et al. Replacement of the alpha5 helix of Galpha16 with Galphas-specific sequences enhances promiscuity of Galpha16 toward Gs-coupled receptors. Cell Signal 2004;16:51-62
136. Takeda S, Okada T, Okamura M, et al. The receptor-Galpha fusion protein as a tool for ligand screening: a model study using a nociceptin receptor-Galphai2 fusion protein. J Biochem (Tokyo) 2004;135:597-604
137. US Patent # 7,208,279
138. Bonacci T, Mathews J, Yuan C, et al. Differential targeting of Gbetagamma-subunit signaling with small molecules. Science 2006;312:443-6
139. Mayer G, Wulffen B, Huber C, et al. An RNA molecule that specifically inhibits G protein-coupled receptor kinase 2 in vitro. RNA 2008 [Epub ahead of print]
140. Roman D, Talbot J, Roof R, et al. Identification of small-molecule inhibitors of RGS4 using a high-throughput flow cytometry protein interaction assay. Mol Pharmacol 2007;71:169-75
141. Galandrin S, Bouvier M. Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol 2006;70:1575-84
142. Krumins A, Barber R. Examination of the effects of increasing Gs protein on beta2-adrenergic receptor, Gs, and adenylyl cyclase interactions. Biochem Pharmacol 1997;54:61-72
143. Waelbroeck M. Activation of guanosine 5′-[gamma-(35)S]thio-triphosphate binding through M(1) muscarinic receptors in transfected Chinese hamster ovary cell membranes; 1. Mathematical analysis of catalytic G protein activation. Mol Pharmacol 2001;59:875-85
144. Hermans E. Biochemical and pharmacological control of the multiplicity of coupling at G protein-coupled receptors. Pharmacol Ther 2003;99:25-44
145. Berg K, Maayani S, Goldfarb J, et al. Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 1998;54:94-104
146. Jarpe M, Knall C, Mitchell F, et al. [D-Arg1,D-Phe5,D-Trp7,9,Leu11] Substance P acts as a biased agonist toward neuropeptide and chemokine receptors. J Biol Chem 1998;273:3097-104
147. Perez D, Karnik S. Multiple signaling states of G protein-coupled receptors. Pharmacol Rev 2005;57:147-61
148. Pineyro G, Archer-Lahlou E. Ligand-specific receptor states: implications for opiate receptor signaling and regulation. Cell Signal 2007;19:8-19
149. Kobilka B, Deupi X. Conformational complexity of G protein-coupled receptors. Trends Pharmacol Sci 2007;28:397-406
150. Kenakin T. Predicting therapeutic value in the lead optimization phase of drug discovery. Nat Rev Drug Discov 2003;2:429-38
151. Tilley D, Rockman H. Role of beta-adrenergic receptor signaling and desensitization in heart failure: new concepts and prospects for treatment. Expert Rev Cardiovasc Ther 2006;4:417-32
152. Xiao R, Zhang S, Chakir K, et al. Enhanced G(i) signaling selectively negates beta2-adrenergic receptor (AR)-but not beta1-AR-mediated positive inotropic effect in myocytes from failing rat hearts. Circulation 2003;108:1633-9
153. Baker J, Hall I, Hill S. Agonist and inverse agonist actions of beta-blockers at the human beta 2-adrenoceptor provide evidence for agonist-directed signaling. Mol Pharmacol 2003;64:1357-69
154. Ponicke K, Groner F, Heinroth-Hoffmann I, et al. Agonist-specific activation of the beta2-adrenoceptor/Gs-protein and beta2-adrenoceptor/ Gi-protein pathway in adult rat ventricular cardiomyocytes. Br J Pharmacol 2006;147:714-9
155. Mazzuco T, Chabre O, Feige J, et al. Aberrant GPCR expression is a sufficient genetic event to trigger adrenocortical tumorigenesis. Mol Cell Endocrinol 2007;265-266:23-8
156. Li S, Huang S, Peng S. Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression. Int J Oncol 2005;27:1329-39
157. Arora P, Ricks T, Trejo J. Protease-activated receptor signaling, endocytic sorting and dysregulation in cancer. J Cell Sci 2007;120:921-8
158. Wang P, DeFea K. Protease-activated receptor-2 simultaneously directs beta-arrestin-1-dependent inhibition and Galphaq-dependent activation of phosphatidylinositol 3-kinase. Biochemistry 2006;45:9374-85
159. Eglen R. Emerging concepts in GPCR function-the influence of cell phenotype on GPCR pharmacology. Proc West Pharmacol Soc 2005;48:31-4
160. Nelson C, Challiss R. 'Phenotypic' pharmacology: the influence of cellular environment on G protein-coupled receptor antagonist and inverse agonist pharmacology. Biochem Pharmacol 2007;73:737-51
161. Torrecilla I, Spragg E, Poulin B, et al. Phosphorylation and regulation of a G protein-coupled receptor by protein kinase CK2. J Cell Biol 2007;177:127-37
162. Kenakin T. Differences between natural and recombinant G protein-coupled receptor systems with varying receptor/G protein stoichiometry. Trends Pharmacol Sci 1997;18:456-64
163. Gonzalez-Maeso J, Rodriguez-Puertas R, Meana J. Quantitative stoichiometry of G proteins activated by mu-opioid receptors in postmortem human brain. Eur J Pharmacol 2002;452:21-33
164. Ernst O, Gramse V, Kolbe M, et al. Monomeric G protein-coupled receptor rhodopsin in solution activates its G protein transducin at the diffusion limit. Proc Natl Acad Sci USA 2007;104:10859-64
165. Philip F, Sengupta P, Scarlata S. Signaling through a G protein-coupled receptor and its corresponding G protein follows a stoichiometrically limited model. J Biol Chem 2007;282:19203-16
166. Zaworski P, Alberts G, Pregenzer J, et al. Efficient functional coupling of the human D3 dopamine receptor to G(o) subtype of G proteins in SH-SY5Y cells. Br J Pharmacol 1999;128:1181-8
167. Chidiac P, Nouet S, Bouvier M. Agonist-induced modulation of inverse agonist efficacy at the beta 2-adrenergic receptor. Mol Pharmacol 1996;50:662-9
168. Pineyro G, Azzi M, deLean A, et al. Reciprocal regulation of agonist and inverse agonist signaling efficacy upon short-term treatment of the human delta-opioid receptor with an inverse agonist. Mol Pharmacol 2005;67:336-48
169. Lane J, Powney B, Wise A, et al. Protean agonism at the dopamine D2 receptor: (S)-3-(3-hydroxyphenyl)-N-propylpiperidine is an agonist for activation of Go1 but an antagonist/inverse agonist for Gi1,Gi2, and Gi3. Mol Pharmacol 2007;71:1349-59
170. Gesty-Palmer D, Chen M, Reiter E, et al. Distinct beta-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J Biol Chem 2006;281:10856-64
171. MacKinnon A, Waters C, Jodrell D, et al. Bombesin and substance P analogs differentially regulate G protein coupling to the bombesin receptor. Direct evidence for biased agonism. J Biol Chem 2001;276:28083-91
172. Jorgensen R, Kubale V, Vrecl M, et al. Oxyntomodulin differentially affects glucagon-like peptide-1 receptor beta-arrestin recruitment and signaling through Galpha(s). J Pharmacol Exp Ther 2007;322:148-54
173. Groer C, Tidgewell K, Moyer R, et al. An opioid agonist that does not induce micro-opioid receptor-arrestin interactions or receptor internalization. Mol Pharmacol 2007;71:549-57
174. Wang Y, Tang K, Inan S, et al. Comparison of pharmacological activities of three distinct ligands (Salvinorin A, TRK-820 and 3FLB) on opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo. J Pharmacol Exp Ther 2005;312:220-30
175. Aplin M, Christensen G, Schneider M, et al. The angiotensin type 1 receptor activates extracellular signal-regulated kinases 1 and 2 by G protein-dependent and -independent pathways in cardiac myocytes and langendorff-perfused hearts. Basic Clin Pharmacol Toxicol 2007;100:289-95
176. Jansson C, Kukkonen J, Nasman J, et al. Protean agonism at alpha2A-adrenoceptors. Mol Pharmacol 1998;53:963-8
177. Watson C, Chen G, Irving P, et al. The use of stimulus-biased assay systems to detect agonist-specific receptor active states: implications for the trafficking of receptor stimulus by agonists. Mol Pharmacol 2000;58:1230-8
178. Mukhopadhyay S, Howlett A. Chemically distinct ligands promote differential CB1 cannabinoid receptor-Gi protein interactions. Mol Pharmacol 2005;67:2016-24
179. Reversi A, Rimoldi V, Marrocco T, et al. The oxytocin receptor antagonist atosiban inhibits cell growth via a 'biased agonist' mechanism. J Biol Chem 2005;280:16311-8
180. Beyermann M, Heinrich N, Fechner K, et al. Achieving signaling selectivity of ligands for the corticotropin-releasing factor type 1 receptor by modifying the agonist's signaling domain. Br J Pharmacol 2007;151:851-9
181. Kukkonen J, Jansson C, Akerman K. Agonist trafficking of G(i/o)-mediated alpha(2A)-adrenoceptor responses in HEL 92.1.7 cells. Br J Pharmacol 2001;132:1477-84
182. Weber T, Markillie L. Regulation of activator protein-1 by 8-iso-prostaglandin E2 in a thromboxane A2 receptor-dependent and -independent manner. Mol Pharmacol 2003;63:1075-81